New cocktail aims to tackle rare lymphoma without chemo

NCT ID NCT07299331

Not yet recruiting Disease control Sponsor: Zhengzhou University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs—zanubrutinib, rituximab, and lenalidomide—as the first treatment for people with marginal zone lymphoma that has spread or requires therapy. Researchers want to see if this drug mix helps tumors shrink or disappear and how safe it is. Fifty adults aged 18 to 75 will take the drugs and visit the clinic regularly for checkups and tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib, rituximab, and lenalidomide
What this could lead to: If successful, this combination could offer a more effective first-line treatment for marginal zone lymphoma, potentially improving remission rates and delaying disease progression.
What could go wrong: This is an early, single-arm study with only 50 participants, so results may not apply broadly. The drug combination can cause side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA (MZL)

More trials for these conditions

Other studies related to the condition(s) this trial covers.